Flexuspine receives FDA conditional approval to begin a feasibility study of its FSU (Functional Spinal Unit) Total Spine Arthroplasty system in the United States.
Pittsburgh, PA - April 22, 2010 - Flexuspine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted conditional approval to begin the initial phase of the Investigational Device Exemption (IDE) for a feasibility study of its FSU device. This is the first approved clinical study for a Total Spine Arthroplasty system in the U.S.
Flexuspine's FSU Total Spinal Segment Replacement is designed to provide an alternative to fusion by reestablishing mobility in an affected segment of the lumbar spine. The device is composed of an interbody disc component (Core) and posterior dynamic resistance component (Dampener) and is designed as a system to restore the motion and natural kinematics of the affected spine segment.
The approval process included an extensive review of Flexuspine’s research, design and biomechanical testing of the FSU device by the FDA, as well as an assessment of Dr. Louis Nel Jr.’s first-in-man clinical series performed in South Africa. “This is a much needed next step in spinal arthroplasty. The potential advantages of this technology could make it the first real ‘total’ level replacement,” commented Dr. Nel.
“The FSU is not like the currently approved disc or facet replacement devices on the market today that only partially rebuild the motion segment. The FSU has three separate parts working together, similar to healthy discs and facets, and is designed to achieve segmental reconstruction from a single posterior approach,” declared Erik Wagner, Chief Technical Officer.
“We are extremely proud of reaching this milestone after completing the tremendous amount of work that went into the development of the FSU device. We are moving into this next phase of our business to verify and validate the science and technology behind the product," stated Vincent Jannetty, President and CEO of Flexuspine.
"We also just recently received multiple ‘notices of allowance of claims’ from the U.S. Patent and Trademark Office. We are very pleased that these claims cover both the system and key features of the product. This recognition by the patent office of the novelty of the system along with the launch of the clinical study, create the solid business foundation we have been working towards,” continued Jannetty.
Flexuspine plans to begin patient enrollment in the U.S. feasibility study very soon while continuing to establish clinical study sites in several countries outside the U.S. The goal of these international studies was, and still is, to collect additional data that may be used in support of a U.S. Pivotal Clinical Trial.
Flexuspine representatives will be attending the below mentioned meetings. There will not be a Flexuspine display booth, so if you are interested in talking with a company representative at any one of these meetings please feel free to contact us to set up an appointment.